Datasheet: MCA1346F

Description:	MOUSE ANTI CAT CD4:FITC
Specificity:	CD4
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	vpg34
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species

Cat

Product Form

Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid

Max Ex/Em

Fluorophore	Excitation Max (nm)	Emission Max (nm)
FITC	490	525

Preparation

Antibody purified from tissue culture supernatant

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.09% sodium azide (NaN_3)
1% bovine serum albumin

Approx. Protein Concentrations

IgG concentration 0.1mg/ml

Immunogen

Immunoaffinity purified feline CD4.

RRID	AB_322909
Fusion Partners	Spleen cells from immunized BALB/c were fused with cells of the NS0 mouse myeloma cell line.
Specificity	**Mouse anti Cat CD4 antibody, clone vpg34** recognizes the feline homolog of the human CD4 antigen. CD4 is not expressed on feline monocytes.
Flow Cytometry	Use 10µl of the suggested working dilution to label 10^6 lymphocytes in 100µl

References

1. Calmann, J.J. *et al.* (1993) Morphologic Characterization of the Lymph Node Changes in Feline Immunodeficiency Virus Infection as an Animal Model of AIDS1 In: Racz P, Letvin NL, Gluckman JC (eds): Animal Models of HIV and Other Retroviral Infections. Basel, Karger, 1993, pp 115-136
2. Willett, B.J. *et al.* (1994) The generation of monoclonal antibodies recognising novel epitopes by immunisation with solid matrix antigen-antibody complexes reveals a polymorphic determinant on feline CD4. J Immunol Methods. 176 (2): 213-20.
3. Hosie, M.J. *et al.* (2000) Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol. 74: 9403-11.
4. Hosie, M.J. *et al.* (2002) Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol. 76: 6062-72.
5. Flynn, J.N. *et al.* (2002) Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J Virol. 76: 2306-15.
6. Campbell, D.J. *et al.* (2004) Insulin-like growth factor-I (IGF-I) and its association with lymphocyte homeostasis in the ageing cat. Mech Ageing Dev. 125: 497-505.
7. Campbell, D.J. *et al.* (2004) Age-related differences in parameters of feline immune status. Vet Immunol Immunopathol. 100: 73-80.
8. Milner, R.J. *et al.* (2004) Suppurative rhinitis associated with *Haemophilus* species infection in a cat. J S Afr Vet Assoc. 75: 103-7.
9. Webb, C. *et al.* (2006) Use of flow cytometry and monochlorobimane to quantitate intracellular glutathione concentrations in feline leukocytes. Vet Immunol Immunopathol. 112 (3-4): 129-40.
10. Veir, J.K. *et al.* (2006) Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg. 8 (6): 400-11.
11. Willett, B.J. *et al.* (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol. 81: 9665-79.
12. Avery, P.R. *et al.* (2007) Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures. Vet Immunol Immunopathol. 117 (3-4): 222-35.
13. Veir, J.K. *et al.* (2007) Effect of supplementation with Enterococcus faecium (SF68) on immune functions in cats. Vet Ther. 8: 229-38.
14. Webb, C. *et al.* (2008) Oxidative stress during acute FIV infection in cats. Vet Immunol Immunopathol. 122 (1-2): 16-24.
15. Carreño, A.D. *et al.* (2008) Loss of naïve (CD45RA+) CD4+ lymphocytes during pediatric infection with feline immunodeficiency virus. Vet Immunol Immunopathol. 121: 161-8.
16. Freer, G. *et al.* (2008) Immunotherapy with internally inactivated virus loaded dendritic

cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course. Retrovirology. 5: 33.
17. Reinero, C.R. *et al.* (2008) Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet Immunol Immunopathol. 121: 241-50.
18. Reche, A.Jr. *et al.* (2010) Cutaneous mycoflora and CD4:CD8 ratio of cats infected with feline immunodeficiency virus. J Feline Med Surg. 12: 355-8.
19. Kraase, M. *et al.* (2010) Feline immunodeficiency virus env gene evolution in experimentally infected cats. Vet Immunol Immunopathol. 134: 96-106.
20. Pistello, M. *et al.* (2010) Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J Virol. 84: 3845-56.
21. Novacco, M. *et al.* (2012) Protection from reinfection in "*Candidatus Mycoplasma turicensis*"-infected cats and characterization of the immune response. Vet Res. 43: 82.
22. Willett, B.J. *et al.* (2013) Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. PLoS One. 8: e54871.
23. Baumann J *et al.* (2015) Lack of cross-protection against *Mycoplasma haemofelis* infection and signs of enhancement in "*Candidatus Mycoplasma turicensis*"-recovered cats. Vet Res. 46: 104.
24. McLuckie, A.J. *et al.* (2016) Detection of *Felis catus* gammaherpesvirus 1 (FcaGHV1) in peripheral blood B- and T-lymphocytes in asymptomatic, naturally-infected domestic cats. Virology. 497: 211-6.
25. Sugiarto, S. *et al.* (2016) Passive immunization does not provide protection against experimental infection with *Mycoplasma haemofelis*. Vet Res. 47 (1): 79.
26. MirandaL, H.M. *et al.* (2018) Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis. PLoS One. 13 (11): e0207644.
27. Sieg, M. *et al.* (2019) A New Genotype of Feline Morbillivirus Infects Primary Cells of the Lung, Kidney, Brain and Peripheral Blood. Viruses. 11 (2) Feb 09 [Epub ahead of print].
28. Maeta, N. *et al.* (2019) Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats. Open Vet J. 9 (2): 147-50.
29. de Oliveira Matheus, L.F. *et al.* (2021) Effects of *Saccharomyces cerevisiae.* cell wall addition on feed digestibility, fecal fermentation and microbiota and immunological parameters in adult cats. BMC Vet Res. 17 (1): 351.
30. Rütgen, B.C. *et al.* (2022) Composition of lymphocyte subpopulations in normal and mildly reactive peripheral lymph nodes in cats. J Feline Med Surg. 24 (2): 77-90.
31. Cha, S. *et al.* (2023) Non-B, Non-T Acute Lymphoblastic Leukemia in a Cat Journal of Veterinary Clinics. 40 (4): 298-302.

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1346F 10041
Regulatory	For research purposes only

Related Products

Recommended Negative Controls

MOUSE IgG1 NEGATIVE CONTROL:FITC (MCA1209F)
MOUSE IgG1 NEGATIVE CONTROL:FITC (MCA928F)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	**Worldwide**	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	**Europe**	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M410374:221028'

Printed on 21 Feb 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint